Literature DB >> 24103783

Characterization of the role of EGF-A of low density lipoprotein receptor in PCSK9 binding.

Hong-mei Gu1, Ayinuer Adijiang, Matthew Mah, Da-wei Zhang.   

Abstract

Proprotein convertase subtilisin kexin-like 9 (PCSK9) promotes the degradation of low density lipoprotein receptor (LDLR) and plays an important role in regulating plasma LDL-cholesterol levels. We have shown that the epidermal growth factor precursor homology domain A (EGF-A) of the LDLR is critical for PCSK9 binding at the cell surface (pH 7.4). Here, we further characterized the role of EGF-A in binding of PCSK9 to the LDLR. We found that PCSK9 efficiently bound to the LDLR but not to other LDLR family members. Replacement of EGF-A in the very low density lipoprotein receptor (VLDLR) with EGF-A of the LDLR promoted the degradation of the mutant VLDLR induced by PCSK9. Furthermore, we found that PCSK9 bound to recombinant EGF-A in a pH-dependent manner with stronger binding at pH 6.0. We also identified amino acid residues in EGF-A of the LDLR important for PCSK9 binding. Mutations G293H, D299V, L318D, and L318H reduced PCSK9 binding to the LDLR at neutral pH without effect at pH 6.0, while mutations R329P and E332G reduced PCSK9 binding at both pH values. Thus, our findings reveal that EGF-A of the LDLR is critical for PCSK9 binding at the cell surface (neutral pH) and at the acidic endosomal environment (pH 6.0), but different determinants contribute to efficient PCSK9 binding in different pH environments.

Entities:  

Keywords:  epidermal growth factor precursor homology domain A; ligand binding; proprotein convertase subtilisin kexin-like 9

Mesh:

Substances:

Year:  2013        PMID: 24103783      PMCID: PMC3826682          DOI: 10.1194/jlr.M041129

Source DB:  PubMed          Journal:  J Lipid Res        ISSN: 0022-2275            Impact factor:   5.922


  48 in total

1.  A mutation in PCSK9 causing autosomal-dominant hypercholesterolemia in a Utah pedigree.

Authors:  Kirsten M Timms; Susanne Wagner; Mark E Samuels; Kristian Forbey; Howard Goldfine; Srikanth Jammulapati; Mark H Skolnick; Paul N Hopkins; Steve C Hunt; Donna M Shattuck
Journal:  Hum Genet       Date:  2004-01-15       Impact factor: 4.132

2.  Cooperation between fixed and low pH-inducible interfaces controls lipoprotein release by the LDL receptor.

Authors:  Natalia Beglova; Hyesung Jeon; Carl Fisher; Stephen C Blacklow
Journal:  Mol Cell       Date:  2004-10-22       Impact factor: 17.970

3.  Low LDL cholesterol in individuals of African descent resulting from frequent nonsense mutations in PCSK9.

Authors:  Jonathan Cohen; Alexander Pertsemlidis; Ingrid K Kotowski; Randall Graham; Christine Kim Garcia; Helen H Hobbs
Journal:  Nat Genet       Date:  2005-01-16       Impact factor: 38.330

4.  Reeler/Disabled-like disruption of neuronal migration in knockout mice lacking the VLDL receptor and ApoE receptor 2.

Authors:  M Trommsdorff; M Gotthardt; T Hiesberger; J Shelton; W Stockinger; J Nimpf; R E Hammer; J A Richardson; J Herz
Journal:  Cell       Date:  1999-06-11       Impact factor: 41.582

5.  Decreased plasma cholesterol and hypersensitivity to statins in mice lacking Pcsk9.

Authors:  Shirya Rashid; David E Curtis; Rita Garuti; Norma N Anderson; Yuriy Bashmakov; Y K Ho; Robert E Hammer; Young-Ah Moon; Jay D Horton
Journal:  Proc Natl Acad Sci U S A       Date:  2005-04-01       Impact factor: 11.205

6.  Overexpression of PCSK9 accelerates the degradation of the LDLR in a post-endoplasmic reticulum compartment.

Authors:  Kara N Maxwell; Edward A Fisher; Jan L Breslow
Journal:  Proc Natl Acad Sci U S A       Date:  2005-01-27       Impact factor: 11.205

Review 7.  Structural features of the low-density lipoprotein receptor facilitating ligand binding and release.

Authors:  N Beglova; H Jeon; C Fisher; S C Blacklow
Journal:  Biochem Soc Trans       Date:  2004-11       Impact factor: 5.407

8.  Mutations in PCSK9 cause autosomal dominant hypercholesterolemia.

Authors:  Marianne Abifadel; Mathilde Varret; Jean-Pierre Rabès; Delphine Allard; Khadija Ouguerram; Martine Devillers; Corinne Cruaud; Suzanne Benjannet; Louise Wickham; Danièle Erlich; Aurélie Derré; Ludovic Villéger; Michel Farnier; Isabel Beucler; Eric Bruckert; Jean Chambaz; Bernard Chanu; Jean-Michel Lecerf; Gerald Luc; Philippe Moulin; Jean Weissenbach; Annick Prat; Michel Krempf; Claudine Junien; Nabil G Seidah; Catherine Boileau
Journal:  Nat Genet       Date:  2003-06       Impact factor: 38.330

9.  Post-transcriptional regulation of low density lipoprotein receptor protein by proprotein convertase subtilisin/kexin type 9a in mouse liver.

Authors:  Sahng Wook Park; Young-Ah Moon; Jay D Horton
Journal:  J Biol Chem       Date:  2004-09-22       Impact factor: 5.157

10.  Self-association of the low density lipoprotein receptor mediated by the cytoplasmic domain.

Authors:  I R van Driel; C G Davis; J L Goldstein; M S Brown
Journal:  J Biol Chem       Date:  1987-11-25       Impact factor: 5.157

View more
  13 in total

1.  APP, APLP2 and LRP1 interact with PCSK9 but are not required for PCSK9-mediated degradation of the LDLR in vivo.

Authors:  Ting Fu; YangYang Guan; Junjie Xu; Yan Wang
Journal:  Biochim Biophys Acta Mol Cell Biol Lipids       Date:  2017-05-09       Impact factor: 4.698

2.  Impacts of ezetimibe on PCSK9 in rats: study on the expression in different organs and the potential mechanisms.

Authors:  Rui-Xia Xu; Jun Liu; Xiao-Lin Li; Sha Li; Yan Zhang; Yan-Jun Jia; Jing Sun; Jian-Jun Li
Journal:  J Transl Med       Date:  2015-03-14       Impact factor: 5.531

Review 3.  Molecular and cellular function of the proprotein convertase subtilisin/kexin type 9 (PCSK9).

Authors:  Rainer Schulz; Klaus-Dieter Schlüter; Ulrich Laufs
Journal:  Basic Res Cardiol       Date:  2015-01-20       Impact factor: 17.165

4.  A New Strategy for Rapidly Screening Natural Inhibitors Targeting the PCSK9/LDLR Interaction In Vitro.

Authors:  Li Li; Chen Shen; Ya-Xuan Huang; Ya-Nan Li; Xiu-Feng Liu; Xu-Ming Liu; Ji-Hua Liu
Journal:  Molecules       Date:  2018-09-19       Impact factor: 4.411

5.  Identification of amino acid residues in the ligand binding repeats of LDL receptor important for PCSK9 binding.

Authors:  Shi-Jun Deng; Adekunle Alabi; Hong-Mei Gu; Ayinuer Adijiang; Shucun Qin; Da-Wei Zhang
Journal:  J Lipid Res       Date:  2019-01-07       Impact factor: 5.922

Review 6.  Cellular Mechanisms of Human Atherogenesis: Focus on Chronification of Inflammation and Mitochondrial Mutations.

Authors:  Alexander M Markin; Igor A Sobenin; Andrey V Grechko; Dongwei Zhang; Alexander N Orekhov
Journal:  Front Pharmacol       Date:  2020-05-14       Impact factor: 5.810

7.  Heterozygous Ldlr-Deficient Hamster as a Model to Evaluate the Efficacy of PCSK9 Antibody in Hyperlipidemia and Atherosclerosis.

Authors:  Yue Wu; Ming-Jiang Xu; Zhiyou Cao; Chun Yang; Jinjie Wang; Bijue Wang; Jian Liu; Yuhui Wang; Xunde Xian; Fang Zhang; George Liu; Xiaoli Chen
Journal:  Int J Mol Sci       Date:  2019-11-26       Impact factor: 5.923

Review 8.  Hypercholesterolemia, low density lipoprotein receptor and proprotein convertase subtilisin/kexin-type 9.

Authors:  Hong-Mei Gu; Da-Wei Zhang
Journal:  J Biomed Res       Date:  2015-07-20

9.  Characterization of the role of a highly conserved sequence in ATP binding cassette transporter G (ABCG) family in ABCG1 stability, oligomerization, and trafficking.

Authors:  Faqi Wang; Ge Li; Hong-mei Gu; Da-wei Zhang
Journal:  Biochemistry       Date:  2013-12-18       Impact factor: 3.162

Review 10.  Familial Hypercholesterolemia: The Most Frequent Cholesterol Metabolism Disorder Caused Disease.

Authors:  Asier Benito-Vicente; Kepa B Uribe; Shifa Jebari; Unai Galicia-Garcia; Helena Ostolaza; Cesar Martin
Journal:  Int J Mol Sci       Date:  2018-11-01       Impact factor: 5.923

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.